Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Last trade$38.26
Day change-$0.795 (-2.04%)
Day range$37.51 – $41.51
Volume144,212
Market cap$1.83B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.83B
Price / earnings
—
Price / book
4.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-19.89×
Profitability
Earnings per share
-$1.59
Return on assets
-16.75%
Return on equity
-17.27%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
33.86×
Quick ratio
33.86×
Cash ratio
18.48×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$89.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COAG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$5.12M
$5.74M
Research and development
$24.64M
$20.34M
Total operating expenses
$30M
$26.08M
Operating income
-$30M
-$26.08M
Interest expense
$0
$0
Income before taxes
-$26.61M
-$24.05M
Income taxes
$693K
$97K
Net income
-$27.3M
-$24.15M
Net income attributable to common shareholders
-$27.3M
-$24.15M
EBITDA
-$29.92M
-$26M
Basic earnings per share
-$0.58
-$0.80
Diluted earnings per share
-$0.58
-$0.80
Recent news
Company coverage with links to the original publishers.
Hemab Therapeutics presented clinical data from HMB-002 showing proof of mechanism in Von Willebrand disease, with dose-dependent increases in VWF and FVIII levels supporting potential monthly subcutaneous dosing. The company also announced HMB-003, a novel non-hormonal antifibrinolytic designed to treat heavy menstrual bleeding with extended duration of action.
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG), a clinical-stage biotechnology company focused on blood coagulation disorder treatments, successfully closed its IPO on May 4, 2026. The company raised approximately $346.7 million through the sale of 19,262,500 shares at $18.00 per share, with underwriters fully exercising their option to purchase an additional 2,512,500 shares. The company's stock began trading on Nasdaq on May 1, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.